Modulation of the urokinase-type plasminogen activator receptor by the β6 integrin subunit

被引:18
作者
Dalvi, N
Thomas, GJ
Marshall, JF
Morgan, M
Bass, R
Ellis, V
Speight, PM
Whawell, SA
机构
[1] UCL, Eastman Dent Inst Oral Hlth Care Sci, Dept Oral Pathol, London WC1X 8LD, England
[2] CRUK, Tumour Biol Lab, John Vane Sci Ctr, London EC1M 6BQ, England
[3] Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England
基金
英国医学研究理事会;
关键词
urokinase; xv beta 36; integrin; cytoplasmic tail; cancer; epithelial cells; melanoma cells;
D O I
10.1016/j.bbrc.2004.02.178
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
over-expression of components of the urokinase system is well documented in cancer and is thought to enable tumour cells to migrate and invade. Changes in integrin expression are also a common feature of tumours and have been linked to changes in protease activity. It has been shown that the alphavalpha6 integrin is neo-expressed in a number of epithelial carcinomas and in wound healing situations. We therefore investigated whether alphavbeta6 is able to modulate a key regulator of proteolysis, the urokinase receptor. We report that epithelial cells expressing full-length alphavbeta6 exhibit decreased urokinase receptor expression and function. Furthermore, this novel modulation requires the C-terminal 11 amino acids of the cytoplasmic tail of the beta6 integrin subunit. Cells expressing alphavbeta3, however, did not affect urokinase receptor expression. De novo expression of beta6 by melanoma cells and beta3 by epithelial cells did not influence urokinase receptor expression or function, suggesting that modulation of urokinase system is both integrin subunit and cell-specific. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:92 / 99
页数:8
相关论文
共 44 条
[1]   αvβ6 integrin-A marker for the malignant potential of epithelial ovarian cancer [J].
Ahmed, N ;
Riley, C ;
Rice, GE ;
Quinn, MA ;
Baker, MS .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2002, 50 (10) :1371-1379
[2]   Overexpression of αvβ6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade [J].
Ahmed, N ;
Pansino, F ;
Clyde, R ;
Murthi, P ;
Quinn, MA ;
Rice, GE ;
Agrez, MV ;
Mok, S ;
Baker, MS .
CARCINOGENESIS, 2002, 23 (02) :237-244
[3]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[4]  
2-Z
[5]   The plasminogen activation system in tumor growth, invasion, and metastasis [J].
Andreasen, PA ;
Egelund, R ;
Petersen, HH .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (01) :25-40
[6]   Significance of α9β31 and αvβ 6 integrin expression in breast carcinoma [J].
Arihiro K. ;
Kaneko M. ;
Fujii S. ;
Inai K. ;
Yokosaki Y. .
Breast Cancer, 2000, 7 (1) :19-26
[7]   The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin:: Implications for antiangiogenic strategies [J].
Bajou, K ;
Masson, V ;
Gerard, RD ;
Schmitt, PM ;
Albert, V ;
Praus, M ;
Lund, LR ;
Frandsen, TL ;
Brunner, N ;
Dano, K ;
Fusenig, NE ;
Weidle, U ;
Carmeliet, G ;
Loskutoff, D ;
Collen, D ;
Carmeliet, P ;
Foidart, JM ;
Noël, AS .
JOURNAL OF CELL BIOLOGY, 2001, 152 (04) :777-784
[8]   beta 1 integrin is essential for teratoma growth and angiogenesis [J].
Bloch, W ;
Forsberg, E ;
Lentini, S ;
Brakebusch, C ;
Martin, K ;
Krell, HW ;
Weidle, UH ;
Addicks, K ;
Fassler, R .
JOURNAL OF CELL BIOLOGY, 1997, 139 (01) :265-278
[9]   UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR, BETA-2-INTEGRINS, AND SRC-KINASES WITHIN A SINGLE RECEPTOR COMPLEX OF HUMAN MONOCYTES [J].
BOHUSLAV, J ;
HOREJSI, V ;
HANSMANN, C ;
STOCKL, J ;
WEIDLE, UH ;
MAJDIC, O ;
BARTKE, I ;
KNAPP, W ;
STOCKINGER, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (04) :1381-1390
[10]  
BREUSS JM, 1995, J CELL SCI, V108, P2241